ReviewNuclear medicine and biology2007
Impact of amyloid imaging on drug development in Alzheimer's disease.
Review in Nuclear medicine and biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 117 citations in OpenAlex.
- A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Ganoderma lucidum Triterpenoids (GLTs) Reduce Neuronal Apoptosis via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice.Oxidative medicine and cellular longevity · 2020Article
- Physical Frailty and Amyloid-β Deposits in the Brains of Older Adults with Cognitive Frailty.Journal of clinical medicine · 2018Article
- Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.Bioinformation · 2018Article
- Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.TheScientificWorldJournal · 2015Review
- Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.Frontiers in neurology · 2015Review
- Molecular imaging as a guide for the treatment of central nervous system disorders.Dialogues in clinical neuroscience · 2013Review
- Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents.Bioorganic & medicinal chemistry letters · 2013Article
- Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins.Current organic chemistry · 2013Article
- Dementia specialists and early adoption of amyloid imaging.Journal of Alzheimer's disease : JAD · 2013Article
- Metal imaging in neurodegenerative diseases.Metallomics : integrated biometal science · 2012Review
- Molecular brain imaging in the multimodality era.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2012Review
- Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.Molecular diagnosis & therapy · 2011Article
- On the emerging role of neuroimaging in determining functional and structural brain integrity induced by physical exercise: impact for predictive, preventive, and personalized medicine.The EPMA journal · 2011Article
- Editorial: can we improve care for patients with dementia?The journal of nutrition, health & aging · 2011Article
- Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.Brain : a journal of neurology · 2011Article
- Article
- Biomarkers in Alzheimer's disease.Frontiers in neurology · 2011Article
- Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease.Nuclear medicine and biology · 2010Article
- Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.Journal of geriatric psychiatry and neurology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Imaging agents capable of assessing amyloid-beta (Abeta) content in vivo in the brains of Alzheimer's disease (AD) subjects likely will be important as diagnostic agents to detect Abeta plaques in the brain as well as to help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of anti-amyloid therapeutics currently under development and in clinical trials. Positron emission tomography (PET) imaging studies of amyloid deposition in human subjects with several Abeta imaging agents are currently underway. We reported the first PET studies of the carbon 11-labeled thioflavin-T derivative Pittsburgh Compound B in 2004, and this work has subsequently been extended to include a variety of subject groups, including AD patients, mild cognitive impairment patients and healthy controls. The ability to quantify regional Abeta plaque load in the brains of living human subjects has provided a means to begin to apply this technology as a diagnostic agent to detect regional concentrations of Abeta plaques and as a surrogate marker of therapeutic efficacy in anti-amyloid drug trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.